HEADER TRANSCRIPTION 09-JUN-06 2H96 TITLE DISCOVERY OF POTENT, HIGHLY SELECTIVE, AND ORALLY BIOAVAILABLE TITLE 2 PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 8; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: JNK1-(1-364)-6HIS; COMPND 5 SYNONYM: STRESS-ACTIVATED PROTEIN KINASE JNK1, C-JUN N-TERMINAL COMPND 6 KINASE 1, JNK-46; COMPND 7 EC: 2.7.11.24; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES; COMPND 10 MOL_ID: 2; COMPND 11 MOLECULE: C-JUN-AMINO-TERMINAL KINASE-INTERACTING PROTEIN 1; COMPND 12 CHAIN: F, G; COMPND 13 FRAGMENT: PEPJIP1 PEPTIDE; COMPND 14 SYNONYM: JNK-INTERACTING PROTEIN 1, JIP-1, JNK MAP KINASE SCAFFOLD COMPND 15 PROTEIN 1, ISLET-BRAIN 1, IB-1, MITOGEN-ACTIVATED PROTEIN KINASE 8- COMPND 16 INTERACTING PROTEIN 1; COMPND 17 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MAPK8, JNK1, PRKM8; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PET28A; SOURCE 9 MOL_ID: 2; SOURCE 10 SYNTHETIC: YES; SOURCE 11 OTHER_DETAILS: THE SEQUENCE IS FOUND NATURALLY IN HOMO SAPIENS SOURCE 12 (HUMAN). KEYWDS JNK1, C-JUN N-TERMINAL KINASE, PROTEIN KINASE JNK1 INHIBITORS, KEYWDS 2 PYRIDINE CARBOXAMIDE INHIBITORS, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR C.ABAD-ZAPATERO REVDAT 6 30-AUG-23 2H96 1 REMARK REVDAT 5 20-OCT-21 2H96 1 REMARK SEQADV REVDAT 4 13-JUL-11 2H96 1 VERSN REVDAT 3 24-FEB-09 2H96 1 VERSN REVDAT 2 01-NOV-06 2H96 1 REMARK REVDAT 1 25-JUL-06 2H96 0 JRNL AUTH H.ZHAO,M.D.SERBY,Z.XIN,B.G.SZCZEPANKIEWICZ,M.LIU,C.KOSOGOF, JRNL AUTH 2 B.LIU,L.T.NELSON,E.F.JOHNSON,S.WANG,T.PEDERSON,R.J.GUM, JRNL AUTH 3 J.E.CLAMPIT,D.L.HAASCH,C.ABAD-ZAPATERO,E.H.FRY,C.RONDINONE, JRNL AUTH 4 J.M.TREVILLYAN,H.L.SHAM,G.LIU JRNL TITL DISCOVERY OF POTENT, HIGHLY SELECTIVE, AND ORALLY JRNL TITL 2 BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE JRNL TITL 3 INHIBITORS. JRNL REF J.MED.CHEM. V. 49 4455 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16854050 JRNL DOI 10.1021/JM060465L REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH B.G.SZCZEPANKIEWICZ,C.KOSOGOF,L.T.NELSON,G.LIU,B.LIU,H.ZHAO, REMARK 1 AUTH 2 M.D.SERBY,Z.XIN,M.LIU,R.J.GUM,D.L.HAASCH,S.WANG,J.E.CLAMPIT, REMARK 1 AUTH 3 E.F.JOHNSON,T.H.LUBBEN,M.A.STASHKO,E.T.OLEJNICZAK,C.SUN, REMARK 1 AUTH 4 S.A.DORWIN,K.HASKINS,C.ABAD-ZAPATERO,E.H.FRY,C.W.HUTCHINS, REMARK 1 AUTH 5 H.L.SHAM,C.M.RONDINONE,J.M.TREVILLYAN REMARK 1 TITL AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH REMARK 1 TITL 2 CELLULAR ACTIVITY AND MINIMAL CROSS-KINASE ACTIVITY. REMARK 1 REF J.MED.CHEM. V. 49 3563 2006 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 16759099 REMARK 1 DOI 10.1021/JM060199B REMARK 1 REFERENCE 2 REMARK 1 AUTH M.LIU,Z.XIN,J.E.CLAMPIT,S.WANG,R.J.GUM,D.L.HAASCH, REMARK 1 AUTH 2 J.M.TREVILLYAN,C.ABAD-ZAPATERO,E.H.FRY,H.L.SHAM,G.LIU REMARK 1 TITL SYNTHESIS AND SAR OF REMARK 1 TITL 2 1,9-DIHYDRO-9-HYDROXYPYRAZOLO[3,4-B]QUINOLIN-4-ONES AS REMARK 1 TITL 3 NOVEL, SELECTIVE C-JUN N-TERMINAL KINASE INHIBITORS. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 16 2590 2006 REMARK 1 REFN ISSN 0960-894X REMARK 1 PMID 16527482 REMARK 1 DOI 10.1016/J.BMCL.2006.02.046 REMARK 2 REMARK 2 RESOLUTION. 3.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.97 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 419658.340 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 79.8 REMARK 3 NUMBER OF REFLECTIONS : 28184 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.243 REMARK 3 R VALUE (WORKING SET) : 0.225 REMARK 3 FREE R VALUE : 0.278 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.900 REMARK 3 FREE R VALUE TEST SET COUNT : 2801 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 31348 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 3.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 3.11 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 54.60 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1713 REMARK 3 BIN R VALUE (WORKING SET) : 0.3180 REMARK 3 BIN FREE R VALUE : 0.3760 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 10.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 193 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.027 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 5939 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 82 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 54.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 59.40 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 8.92000 REMARK 3 B22 (A**2) : 8.92000 REMARK 3 B33 (A**2) : -17.83000 REMARK 3 B12 (A**2) : 29.47000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.37 REMARK 3 ESD FROM SIGMAA (A) : 0.45 REMARK 3 LOW RESOLUTION CUTOFF (A) : 6.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.48 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.56 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.90 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.870 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.30 REMARK 3 BSOL : 25.05 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : ACCELRYS_CNX_TOPPAR:PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : GCR.PAR REMARK 3 PARAMETER FILE 3 : ACCELRYS_CNX_TOPPAR:ION.PARAM REMARK 3 PARAMETER FILE 4 : 893.PAR REMARK 3 PARAMETER FILE 5 : SO4.PAR REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : GCR.TOP REMARK 3 TOPOLOGY FILE 3 : ACCELRYS_CNX_TOPPAR:ION.PARAM REMARK 3 TOPOLOGY FILE 4 : 893.TOP REMARK 3 TOPOLOGY FILE 5 : SO4.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 DUE TO A FEATURE IN THE REFINEMENT PROGRAM, THE STRUCTURE WAS REMARK 3 REFINED WITH OXT ON ONE OR MORE RESIDUES THAT IS NOT THE TERMINAL REMARK 3 RESIDUE OF THE SEQUENCE. IN ALL THESE INSTANCES THE OXT WAS REMARK 3 CHANGED TO N OF THE NEXT RESIDUE. REMARK 3 REMARK 3 THE AUTHOR STATES: REMARK 3 ALTHOUGH THE DATA IN THE HIGHEST RESOLUTION SHELL REMARK 3 HAD POOR AGREEMENT FACTOR, IT WAS DECIDED TO INCLUDE REMARK 3 THEM IN THE REFINEMENT BECAUSE THEY WERE RELATIVELY STRONG REMARK 3 FOR THESE WEAK-DIFFRACTING CRYSTALS AND TO ADD MORE DATA REMARK 3 GIVEN THE LARGE NUMBER OF ATOMS IN THE ASYMMETRIC UNIT. REMARK 3 REMARK 3 REMARK 3 THE REFINEMENT OF INDIVIDUAL, RESTRAINT, B-FACTORS DROPPED REMARK 3 BOTH THE R- AND THE R-FREE AND SO IT WAS CONSIDERED TO BE REMARK 3 REASONABLE. HOWEVER, THE INDIVIDUAL VALUES REFLECT MORE REMARK 3 TRENDS THAN INDIVIDUAL DIFFERENCES. THEY HAVE BEEN REMARK 3 RETAINED IN THE ENTRY SPECIALLY TO SHOW DIFFERENCES BETWEEN REMARK 3 THE SO4 IONS AND LIGANDS, AND AMONG DIFFERENT AMINO ACIDS REMARK 3 IN THE CHAIN. THE DIFFERENCES AMONG INDIVDUAL ATOMS/GROUPS REMARK 3 WITHIN EACH RESIDUE SHOULD BE CONSIDERED ONLY AS A TREND. REMARK 4 REMARK 4 2H96 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-JUN-06. REMARK 100 THE DEPOSITION ID IS D_1000038086. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-OCT-04 REMARK 200 TEMPERATURE (KELVIN) : 110.0 REMARK 200 PH : 6.20 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 31447 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.000 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.1 REMARK 200 DATA REDUNDANCY : 7.200 REMARK 200 R MERGE (I) : 0.09400 REMARK 200 R SYM (I) : 0.09400 REMARK 200 FOR THE DATA SET : 22.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.11 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 6.80 REMARK 200 R MERGE FOR SHELL (I) : 0.75400 REMARK 200 R SYM FOR SHELL (I) : 0.75400 REMARK 200 FOR SHELL : 2.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: 2G01 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 75.11 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 4.94 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PROTEIN WAS PREINCUBATED WITH THE JIP1 REMARK 280 PEPTIDE AT A 5X MOLAR EXCESS. PROTEIN CONCENTRATION 9- 12.6 MG/ REMARK 280 ML. HANGING DROPS CONSISTED OF 2UL PROTEIN PLUS 2 UL WELL REMARK 280 SOLUTION. WELL SOLUTION:2.8-3.1 M AMMONIUM SULFATE, 10- 14% REMARK 280 GLYCEROL. FOR CO-CRYSTALLIZATION EXPERIMENT WITH THE COMPOUND, REMARK 280 THE COMPOUND WAS DISSOLVED IN DMSO AT 100 MM CONCENTRATION. REMARK 280 ALLOW TO INCUBATE FOR AT LEAST AN HOUR ON ICE. SOLUTION WAS SPUN REMARK 280 FOR 5 MINUTES AT 2000G PRIOR TO SETTING UP FOR CRYSTALLIZATION, REMARK 280 PH 6.2, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277.0K, PH REMARK 280 6.20 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 83.44200 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 41.72100 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 41.72100 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 83.44200 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1950 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 17390 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -36.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1950 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 16480 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -39.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, G REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5370 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 32400 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -96.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, F, B, G REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 ARG A 3 REMARK 465 SER A 4 REMARK 465 LYS A 5 REMARK 465 ARG A 6 REMARK 465 HIS A 366 REMARK 465 HIS A 367 REMARK 465 HIS A 368 REMARK 465 HIS A 369 REMARK 465 HIS A 370 REMARK 465 ARG F 553 REMARK 465 MET B 1 REMARK 465 SER B 2 REMARK 465 ARG B 3 REMARK 465 SER B 4 REMARK 465 LYS B 5 REMARK 465 ARG B 6 REMARK 465 HIS B 365 REMARK 465 HIS B 366 REMARK 465 HIS B 367 REMARK 465 HIS B 368 REMARK 465 HIS B 369 REMARK 465 HIS B 370 REMARK 465 ARG G 553 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 185 CG CD OE1 OE2 REMARK 470 GLU A 346 CG CD OE1 OE2 REMARK 470 LYS A 358 CG CD CE NZ REMARK 470 HIS A 365 CA C O CB CG ND1 CD2 REMARK 470 HIS A 365 CE1 NE2 REMARK 470 LYS B 358 CG CD CE NZ REMARK 470 GLU B 364 CA C O CB CG CD OE1 REMARK 470 GLU B 364 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 8 21.84 -78.70 REMARK 500 ASN A 9 33.08 75.37 REMARK 500 PHE A 10 -128.36 -143.78 REMARK 500 TYR A 11 164.71 130.10 REMARK 500 GLU A 14 80.75 -66.38 REMARK 500 SER A 18 -158.67 -119.69 REMARK 500 THR A 21 104.93 -160.36 REMARK 500 LYS A 24 -44.90 -22.72 REMARK 500 ARG A 25 -28.13 -38.75 REMARK 500 ILE A 32 -27.37 -158.03 REMARK 500 ALA A 46 -70.00 -59.06 REMARK 500 ILE A 47 -31.55 -37.83 REMARK 500 GLU A 49 34.37 71.32 REMARK 500 ARG A 59 75.92 48.15 REMARK 500 GLU A 73 -71.33 -48.46 REMARK 500 LEU A 74 -78.04 -42.17 REMARK 500 VAL A 75 -67.14 -28.22 REMARK 500 CYS A 79 0.55 -66.33 REMARK 500 ASN A 90 -179.82 -174.23 REMARK 500 LEU A 98 -32.43 -38.06 REMARK 500 PHE A 101 130.27 -23.98 REMARK 500 GLN A 102 -7.43 176.77 REMARK 500 GLU A 109 156.44 -49.44 REMARK 500 ILE A 119 -8.76 -50.74 REMARK 500 HIS A 125 -37.73 -39.59 REMARK 500 ASP A 151 46.02 -155.19 REMARK 500 ASP A 169 140.71 47.60 REMARK 500 PHE A 170 -1.15 -141.49 REMARK 500 ALA A 176 -161.04 82.86 REMARK 500 THR A 178 -74.06 -43.91 REMARK 500 SER A 179 176.95 -52.22 REMARK 500 MET A 181 94.63 83.08 REMARK 500 ARG A 189 -68.01 -11.43 REMARK 500 LEU A 198 37.31 -92.98 REMARK 500 LYS A 203 -163.70 -105.29 REMARK 500 HIS A 221 10.24 83.55 REMARK 500 PRO A 226 -145.08 -53.41 REMARK 500 LYS A 250 -7.63 -58.05 REMARK 500 VAL A 278 -24.84 -35.68 REMARK 500 PRO A 281 174.09 -54.12 REMARK 500 SER A 284 -107.41 -86.05 REMARK 500 GLU A 285 -8.58 -146.79 REMARK 500 ILE A 310 174.20 -46.44 REMARK 500 TRP A 324 -10.88 -163.14 REMARK 500 SER A 328 -71.56 -56.98 REMARK 500 GLU A 331 51.40 -110.92 REMARK 500 ALA A 332 -168.42 -54.79 REMARK 500 ASP A 339 3.16 168.10 REMARK 500 LEU A 342 -111.19 -148.77 REMARK 500 ASP A 343 -22.80 -166.46 REMARK 500 REMARK 500 THIS ENTRY HAS 109 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 893 A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 893 B 902 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 702 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2G01 RELATED DB: PDB REMARK 900 PYRAZOLOQUINOLONES AS NOVEL, SELECTIVE JNK1 INHIBITORS REMARK 900 RELATED ID: 2GMX RELATED DB: PDB REMARK 900 SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS REMARK 900 WITH CELLULAR ACTIVITY REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE NATIVE, UNMUTATED SEQUENCE IS THE SAME AS REMARK 999 THE P45983-2 ISOFORM. THE INTRODUCED MUTATIONS REMARK 999 (THR183>GLU, TYR185>GLU) ARE INTENDED TO MIMIC REMARK 999 THE ACTIVATED FORM OF THE KINASE UPON REMARK 999 PHOSPHORYLATION OF THOSE TWO RESIDUES. DBREF 2H96 A 1 364 UNP P45983 MK08_HUMAN 1 364 DBREF 2H96 B 1 364 UNP P45983 MK08_HUMAN 1 364 DBREF 2H96 F 553 563 UNP Q9UQF2 JIP1_HUMAN 157 167 DBREF 2H96 G 553 563 UNP Q9UQF2 JIP1_HUMAN 157 167 SEQADV 2H96 GLU A 183 UNP P45983 THR 183 ENGINEERED MUTATION SEQADV 2H96 GLU A 185 UNP P45983 TYR 185 ENGINEERED MUTATION SEQADV 2H96 HIS A 365 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS A 366 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS A 367 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS A 368 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS A 369 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS A 370 UNP P45983 EXPRESSION TAG SEQADV 2H96 GLU B 183 UNP P45983 THR 183 ENGINEERED MUTATION SEQADV 2H96 GLU B 185 UNP P45983 TYR 185 ENGINEERED MUTATION SEQADV 2H96 HIS B 365 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS B 366 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS B 367 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS B 368 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS B 369 UNP P45983 EXPRESSION TAG SEQADV 2H96 HIS B 370 UNP P45983 EXPRESSION TAG SEQRES 1 A 370 MET SER ARG SER LYS ARG ASP ASN ASN PHE TYR SER VAL SEQRES 2 A 370 GLU ILE GLY ASP SER THR PHE THR VAL LEU LYS ARG TYR SEQRES 3 A 370 GLN ASN LEU LYS PRO ILE GLY SER GLY ALA GLN GLY ILE SEQRES 4 A 370 VAL CYS ALA ALA TYR ASP ALA ILE LEU GLU ARG ASN VAL SEQRES 5 A 370 ALA ILE LYS LYS LEU SER ARG PRO PHE GLN ASN GLN THR SEQRES 6 A 370 HIS ALA LYS ARG ALA TYR ARG GLU LEU VAL LEU MET LYS SEQRES 7 A 370 CYS VAL ASN HIS LYS ASN ILE ILE GLY LEU LEU ASN VAL SEQRES 8 A 370 PHE THR PRO GLN LYS SER LEU GLU GLU PHE GLN ASP VAL SEQRES 9 A 370 TYR ILE VAL MET GLU LEU MET ASP ALA ASN LEU CYS GLN SEQRES 10 A 370 VAL ILE GLN MET GLU LEU ASP HIS GLU ARG MET SER TYR SEQRES 11 A 370 LEU LEU TYR GLN MET LEU CYS GLY ILE LYS HIS LEU HIS SEQRES 12 A 370 SER ALA GLY ILE ILE HIS ARG ASP LEU LYS PRO SER ASN SEQRES 13 A 370 ILE VAL VAL LYS SER ASP CYS THR LEU LYS ILE LEU ASP SEQRES 14 A 370 PHE GLY LEU ALA ARG THR ALA GLY THR SER PHE MET MET SEQRES 15 A 370 GLU PRO GLU VAL VAL THR ARG TYR TYR ARG ALA PRO GLU SEQRES 16 A 370 VAL ILE LEU GLY MET GLY TYR LYS GLU ASN VAL ASP LEU SEQRES 17 A 370 TRP SER VAL GLY CYS ILE MET GLY GLU MET VAL CYS HIS SEQRES 18 A 370 LYS ILE LEU PHE PRO GLY ARG ASP TYR ILE ASP GLN TRP SEQRES 19 A 370 ASN LYS VAL ILE GLU GLN LEU GLY THR PRO CYS PRO GLU SEQRES 20 A 370 PHE MET LYS LYS LEU GLN PRO THR VAL ARG THR TYR VAL SEQRES 21 A 370 GLU ASN ARG PRO LYS TYR ALA GLY TYR SER PHE GLU LYS SEQRES 22 A 370 LEU PHE PRO ASP VAL LEU PHE PRO ALA ASP SER GLU HIS SEQRES 23 A 370 ASN LYS LEU LYS ALA SER GLN ALA ARG ASP LEU LEU SER SEQRES 24 A 370 LYS MET LEU VAL ILE ASP ALA SER LYS ARG ILE SER VAL SEQRES 25 A 370 ASP GLU ALA LEU GLN HIS PRO TYR ILE ASN VAL TRP TYR SEQRES 26 A 370 ASP PRO SER GLU ALA GLU ALA PRO PRO PRO LYS ILE PRO SEQRES 27 A 370 ASP LYS GLN LEU ASP GLU ARG GLU HIS THR ILE GLU GLU SEQRES 28 A 370 TRP LYS GLU LEU ILE TYR LYS GLU VAL MET ASP LEU GLU SEQRES 29 A 370 HIS HIS HIS HIS HIS HIS SEQRES 1 F 11 ARG PRO LYS ARG PRO THR THR LEU ASN LEU PHE SEQRES 1 B 370 MET SER ARG SER LYS ARG ASP ASN ASN PHE TYR SER VAL SEQRES 2 B 370 GLU ILE GLY ASP SER THR PHE THR VAL LEU LYS ARG TYR SEQRES 3 B 370 GLN ASN LEU LYS PRO ILE GLY SER GLY ALA GLN GLY ILE SEQRES 4 B 370 VAL CYS ALA ALA TYR ASP ALA ILE LEU GLU ARG ASN VAL SEQRES 5 B 370 ALA ILE LYS LYS LEU SER ARG PRO PHE GLN ASN GLN THR SEQRES 6 B 370 HIS ALA LYS ARG ALA TYR ARG GLU LEU VAL LEU MET LYS SEQRES 7 B 370 CYS VAL ASN HIS LYS ASN ILE ILE GLY LEU LEU ASN VAL SEQRES 8 B 370 PHE THR PRO GLN LYS SER LEU GLU GLU PHE GLN ASP VAL SEQRES 9 B 370 TYR ILE VAL MET GLU LEU MET ASP ALA ASN LEU CYS GLN SEQRES 10 B 370 VAL ILE GLN MET GLU LEU ASP HIS GLU ARG MET SER TYR SEQRES 11 B 370 LEU LEU TYR GLN MET LEU CYS GLY ILE LYS HIS LEU HIS SEQRES 12 B 370 SER ALA GLY ILE ILE HIS ARG ASP LEU LYS PRO SER ASN SEQRES 13 B 370 ILE VAL VAL LYS SER ASP CYS THR LEU LYS ILE LEU ASP SEQRES 14 B 370 PHE GLY LEU ALA ARG THR ALA GLY THR SER PHE MET MET SEQRES 15 B 370 GLU PRO GLU VAL VAL THR ARG TYR TYR ARG ALA PRO GLU SEQRES 16 B 370 VAL ILE LEU GLY MET GLY TYR LYS GLU ASN VAL ASP LEU SEQRES 17 B 370 TRP SER VAL GLY CYS ILE MET GLY GLU MET VAL CYS HIS SEQRES 18 B 370 LYS ILE LEU PHE PRO GLY ARG ASP TYR ILE ASP GLN TRP SEQRES 19 B 370 ASN LYS VAL ILE GLU GLN LEU GLY THR PRO CYS PRO GLU SEQRES 20 B 370 PHE MET LYS LYS LEU GLN PRO THR VAL ARG THR TYR VAL SEQRES 21 B 370 GLU ASN ARG PRO LYS TYR ALA GLY TYR SER PHE GLU LYS SEQRES 22 B 370 LEU PHE PRO ASP VAL LEU PHE PRO ALA ASP SER GLU HIS SEQRES 23 B 370 ASN LYS LEU LYS ALA SER GLN ALA ARG ASP LEU LEU SER SEQRES 24 B 370 LYS MET LEU VAL ILE ASP ALA SER LYS ARG ILE SER VAL SEQRES 25 B 370 ASP GLU ALA LEU GLN HIS PRO TYR ILE ASN VAL TRP TYR SEQRES 26 B 370 ASP PRO SER GLU ALA GLU ALA PRO PRO PRO LYS ILE PRO SEQRES 27 B 370 ASP LYS GLN LEU ASP GLU ARG GLU HIS THR ILE GLU GLU SEQRES 28 B 370 TRP LYS GLU LEU ILE TYR LYS GLU VAL MET ASP LEU GLU SEQRES 29 B 370 HIS HIS HIS HIS HIS HIS SEQRES 1 G 11 ARG PRO LYS ARG PRO THR THR LEU ASN LEU PHE HET SO4 A 501 5 HET SO4 A 502 5 HET 893 A 901 25 HET GOL A 701 6 HET SO4 B 601 5 HET SO4 B 602 5 HET 893 B 902 25 HET GOL B 702 6 HETNAM SO4 SULFATE ION HETNAM 893 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2- HETNAM 2 893 CARBOXAMIDE HETNAM GOL GLYCEROL HETSYN 893 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPICOLINAMIDE; HETSYN 2 893 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2- HETSYN 3 893 CARBOXAMIDE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 5 SO4 4(O4 S 2-) FORMUL 7 893 2(C18 H19 N3 O4) FORMUL 8 GOL 2(C3 H8 O3) HELIX 1 1 ASN A 63 VAL A 80 1 18 HELIX 2 2 LEU A 115 ILE A 119 1 5 HELIX 3 3 ASP A 124 SER A 144 1 21 HELIX 4 4 LYS A 153 SER A 155 5 3 HELIX 5 5 GLU A 183 VAL A 187 5 5 HELIX 6 6 THR A 188 ARG A 192 5 5 HELIX 7 7 ALA A 193 LEU A 198 1 6 HELIX 8 8 ASN A 205 HIS A 221 1 17 HELIX 9 9 ILE A 231 GLY A 242 1 12 HELIX 10 10 CYS A 245 LYS A 250 1 6 HELIX 11 11 GLN A 253 ASN A 262 1 10 HELIX 12 12 SER A 270 PHE A 275 1 6 HELIX 13 13 PRO A 276 PHE A 280 5 5 HELIX 14 14 LYS A 290 LEU A 302 1 13 HELIX 15 15 ASP A 305 ARG A 309 5 5 HELIX 16 16 SER A 311 LEU A 316 1 6 HELIX 17 17 ASP A 326 GLU A 331 1 6 HELIX 18 18 THR A 348 MET A 361 1 14 HELIX 19 19 ASN B 63 VAL B 80 1 18 HELIX 20 20 LEU B 115 GLN B 120 1 6 HELIX 21 21 ASP B 124 SER B 144 1 21 HELIX 22 22 LYS B 153 SER B 155 5 3 HELIX 23 23 GLU B 183 VAL B 187 5 5 HELIX 24 24 THR B 188 ARG B 192 5 5 HELIX 25 25 ALA B 193 LEU B 198 1 6 HELIX 26 26 LYS B 203 ASN B 205 5 3 HELIX 27 27 VAL B 206 HIS B 221 1 16 HELIX 28 28 ILE B 231 LEU B 241 1 11 HELIX 29 29 CYS B 245 LYS B 250 1 6 HELIX 30 30 GLN B 253 ARG B 263 1 11 HELIX 31 31 PRO B 276 PHE B 280 5 5 HELIX 32 32 LYS B 290 LEU B 302 1 13 HELIX 33 33 ASP B 305 ARG B 309 5 5 HELIX 34 34 SER B 311 GLN B 317 1 7 HELIX 35 35 HIS B 318 VAL B 323 1 6 HELIX 36 36 ASP B 326 GLU B 331 1 6 HELIX 37 37 THR B 348 ASP B 362 1 15 SHEET 1 A 5 TYR A 26 GLY A 33 0 SHEET 2 A 5 VAL A 40 ASP A 45 -1 O VAL A 40 N GLY A 33 SHEET 3 A 5 ARG A 50 LYS A 56 -1 O VAL A 52 N ALA A 43 SHEET 4 A 5 TYR A 105 GLU A 109 -1 O ILE A 106 N LYS A 55 SHEET 5 A 5 LEU A 88 PHE A 92 -1 N PHE A 92 O TYR A 105 SHEET 1 B 3 ALA A 113 ASN A 114 0 SHEET 2 B 3 ILE A 157 LYS A 160 -1 O VAL A 159 N ALA A 113 SHEET 3 B 3 THR A 164 ILE A 167 -1 O LYS A 166 N VAL A 158 SHEET 1 C 2 ILE A 147 ILE A 148 0 SHEET 2 C 2 ARG A 174 THR A 175 -1 O ARG A 174 N ILE A 148 SHEET 1 D 2 SER B 12 VAL B 13 0 SHEET 2 D 2 PHE B 20 THR B 21 -1 O PHE B 20 N VAL B 13 SHEET 1 E 5 TYR B 26 GLY B 33 0 SHEET 2 E 5 VAL B 40 ASP B 45 -1 O ALA B 42 N LYS B 30 SHEET 3 E 5 ARG B 50 LYS B 56 -1 O VAL B 52 N ALA B 43 SHEET 4 E 5 TYR B 105 GLU B 109 -1 O MET B 108 N ALA B 53 SHEET 5 E 5 LEU B 88 PHE B 92 -1 N ASN B 90 O VAL B 107 SHEET 1 F 2 ILE B 157 VAL B 159 0 SHEET 2 F 2 LEU B 165 ILE B 167 -1 O LYS B 166 N VAL B 158 SITE 1 AC1 4 ARG A 189 ARG A 192 TYR A 230 THR B 255 SITE 1 AC2 4 LYS A 68 ARG A 69 ARG A 150 GLU A 183 SITE 1 AC3 4 THR A 255 ARG B 189 ARG B 192 TYR B 230 SITE 1 AC4 4 LYS B 68 ARG B 69 ARG B 150 ARG B 174 SITE 1 AC5 11 ILE A 32 VAL A 40 ALA A 42 LYS A 55 SITE 2 AC5 11 MET A 108 LEU A 110 MET A 111 ASP A 112 SITE 3 AC5 11 ALA A 113 VAL A 158 LEU A 168 SITE 1 AC6 12 ARG A 50 ILE B 32 VAL B 40 LYS B 55 SITE 2 AC6 12 MET B 108 LEU B 110 MET B 111 ASP B 112 SITE 3 AC6 12 ALA B 113 ASN B 114 VAL B 158 LEU B 168 SITE 1 AC7 2 ILE A 197 LEU A 198 SITE 1 AC8 3 TYR A 230 ILE B 197 VAL B 256 CRYST1 155.660 155.660 125.163 90.00 90.00 120.00 P 32 2 1 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.006424 0.003709 0.000000 0.00000 SCALE2 0.000000 0.007418 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007990 0.00000